Oxford Biomedica Names Leone Patterson Non-Executive Director

Oxford Biomedica plc, an innovation-led viral vector contract development and manufacturing organization (CDMO), has appointed Leone Patterson, Independent Non-Executive Director. Patterson will join the board on May 1.

Patterson has more than 20 years of public company biotech experience including in the cell and gene therapy industry and has managed significant growth within international commercial companies working across areas including strategy, finance, operations and governance.

Patterson is currently the chief financial and business officer at Tenaya Therapeutics, a clinical-stage company with a mission to discover, develop, and deliver potentially curative therapies, including gene therapy for heart disease. She also serves on the board of directors for Nkarta, a clinical-stage cell therapy company.

Previously, Patterson held leadership roles, including CEO and chief financial officer, at Adverum Biotechnologies, a gene therapy company focused on rare and ocular diseases. She has also held the role of chief financial officer at public companies, including diagnostics firm Diadexus and specialty pharmaceuticals provider Transcept Pharmaceuticals and, earlier in her career, worked within Novartis, Chiron and KPMG.

Roch Doliveux, chair of Oxford Biomedica, said: “The appointment of Leone comes at an important juncture for Oxford Biomedica, as we advance our global leadership in viral vector development and supply, providing innovative solutions to our international biopharma customers. Leone’s deep understanding of corporate finance, her experience of the US public markets and M&A, in addition to her extensive experience in the cell and gene therapy industry will be invaluable in supporting our international strategy and further strengthening our market position.”